Literature DB >> 16179017

Chagasic patients with indeterminate clinical form of the disease have high frequencies of circulating CD3+CD16-CD56+ natural killer T cells and CD4+CD25High regulatory T lymphocytes.

D M Vitelli-Avelar1, R Sathler-Avelar, J C P Dias, V P M Pascoal, A Teixeira-Carvalho, P S Lage, S M Elói-Santos, R Corrêa-Oliveira, O A Martins-Filho.   

Abstract

Several studies have demonstrated that different clinical manifestations of human Chagas' disease are associated with distinct and complex host-parasite relationships directly involving the immune system. In this context, it has been proposed that tissue damage might be more severe in the absence of regulatory mechanisms that involve both innate and adaptive immune responses. Herein, we describe a descriptive phenotypic profile focusing on the frequency of major regulatory T cells [CD4+CD25high and natural killer T (NKT) lymphocytes] in different clinical forms of Chagas' disease. Ex vivo immunophenotyping of whole blood demonstrated that the indeterminate clinical form displays a higher frequency of both CD4+CD25high and NKT regulatory cells (CD3+CD16-CD56+), associated with increased levels of circulating cytotoxic NK cells (CD3-CD16+CD56+ and CD3-CD16+CD56dim NK cells). By contrast, the increased percentage of activated CD8+HLA-DR+ T-cell subset was exclusively associated with severe clinical forms of Chagas' disease. We hypothesize that regulatory T cells may be able to control the deleterious cytotoxic activity in the indeterminate clinical form by inhibiting the activation of CD8+HLA-DR+ T cells. The lack of regulated populations in cardiac and digestive clinical forms could account for impaired immune response that culminates in strong cytotoxic activity and tissue damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16179017     DOI: 10.1111/j.1365-3083.2005.01668.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  27 in total

Review 1.  Regulatory T cells in microbial infection.

Authors:  Jocelyne Demengeot; Santiago Zelenay; Maria Francisca Moraes-Fontes; Iris Caramalho; António Coutinho
Journal:  Springer Semin Immunopathol       Date:  2006-07-28

2.  Are increased frequency of macrophage-like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas' disease morbidity?

Authors:  D M Vitelli-Avelar; R Sathler-Avelar; R L Massara; J D Borges; P S Lage; M Lana; A Teixeira-Carvalho; J C P Dias; S M Elói-Santos; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

3.  Regulation of Trypanosoma cruzi-induced myocarditis by programmed death cell receptor 1.

Authors:  Fredy R S Gutierrez; Flávia S Mariano; Carlo J F Oliveira; Wander R Pavanelli; Paulo M M Guedes; Grace K Silva; Ana P Campanelli; Cristiane M Milanezi; Miyuki Azuma; Tasuku Honjo; Mauro M Teixeira; Julio C S Aliberti; João S Silva
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

4.  Blood Gene Signatures of Chagas Cardiomyopathy With or Without Ventricular Dysfunction.

Authors:  Ludmila Rodrigues Pinto Ferreira; Frederico Moraes Ferreira; Helder Imoto Nakaya; Xutao Deng; Darlan da Silva Cândido; Lea Campos de Oliveira; Jean-Noel Billaud; Marion C Lanteri; Vagner Oliveira-Carvalho Rigaud; Mark Seielstad; Jorge Kalil; Fabio Fernandes; Antonio Luiz P Ribeiro; Ester Cerdeira Sabino; Edecio Cunha-Neto
Journal:  J Infect Dis       Date:  2017-02-01       Impact factor: 5.226

Review 5.  Understanding CD8+ T Cell Immunity to Trypanosoma cruzi and How to Improve It.

Authors:  Eva V Acosta Rodríguez; Cintia L Araujo Furlan; Facundo Fiocca Vernengo; Carolina L Montes; Adriana Gruppi
Journal:  Trends Parasitol       Date:  2019-10-10

6.  T-Cell Immunophenotyping and Cytokine Production Analysis in Patients with Chagas Disease 4 Years after Benznidazole Treatment.

Authors:  Mauricio Llaguno; Marcos Vinicius da Silva; Lara Rocha Batista; Djalma Alexandre Alves da Silva; Rodrigo Cunha de Sousa; Luiz Antonio Pertili Rodrigues de Resende; Valdo Jose Dias da Silva; Eliane Lages-Silva; Carlo José Freire Oliveira; Juliana Reis Machado; Denise Bertulucci Rocha Rodrigues; Dalmo Correia; Virmondes Rodrigues
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

7.  Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.

Authors:  Maria Luiza Silva; Luçandra Ramos Espírito-Santo; Marina Angela Martins; Denise Silveira-Lemos; Vanessa Peruhype-Magalhães; Ricardo Carvalho Caminha; Péricles de Andrade Maranhão-Filho; Maria Auxiliadora-Martins; Reinaldo de Menezes Martins; Ricardo Galler; Marcos da Silva Freire; Rugimar Marcovistz; Akira Homma; Dirk E Teuwen; Silvana Maria Elói-Santos; Mariléia Chaves Andrade; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Clin Vaccine Immunol       Date:  2009-11-11

Review 8.  Pathology and Pathogenesis of Chagas Heart Disease.

Authors:  Kevin M Bonney; Daniel J Luthringer; Stacey A Kim; Nisha J Garg; David M Engman
Journal:  Annu Rev Pathol       Date:  2018-10-24       Impact factor: 23.472

9.  NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Eliana A G Reis; Daniel A Athanazio; Isabella Lima; Natália Oliveira e Silva; Jorge Clarencio S Andrade; Ronden N Jesus; Lúcio M Barbosa; Mitermayer G Reis; Mittermayer B Santiago
Journal:  Rheumatol Int       Date:  2008-09-28       Impact factor: 2.631

10.  Increase in the expression of CD4 + CD25+ lymphocytic T cells in the indeterminate clinical form of human Chagas disease after stimulation with recombinant antigens of Trypanosoma cruzi.

Authors:  Suellen Carvalho de Moura Braz; Adriene Siqueira de Melo; Maria da Glória Aureliano de Melo Cavalcanti; Sílvia Marinho Martins; Wilson de Oliveira; Edimilson Domingos da Silva; Antonio Gomes Pinto Ferreira; Virginia Maria Barros de Lorena; Yara de Miranda Gomes
Journal:  J Clin Immunol       Date:  2014-09-10       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.